These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 20938131)

  • 1. New uremic toxins - which solutes should be removed?
    Glorieux G; Vanholder R
    Contrib Nephrol; 2011; 168():117-128. PubMed ID: 20938131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beta-2-microglobulin as a uremic toxin: the Japanese experience.
    Fujimori A
    Contrib Nephrol; 2011; 168():129-133. PubMed ID: 20938132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of hemodialysis patients and uremic toxin removal.
    Vanholder R; Smet RD; Glorieux G; Dhondt A
    Artif Organs; 2003 Mar; 27(3):218-23. PubMed ID: 12662205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Release of uremic retention solutes from protein binding by hypertonic predilution hemodiafiltration.
    Böhringer F; Jankowski V; Gajjala PR; Zidek W; Jankowski J
    ASAIO J; 2015; 61(1):55-60. PubMed ID: 25419832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for a New Classification of Solutes of Interest in Chronic Kidney Disease and Hemodialysis.
    Reis T; Hutchison C; de Assis Rocha Neves F; Zawadzki B; Zanella M; Ronco C; Rosner MH
    Blood Purif; 2023; 52(3):242-254. PubMed ID: 36657410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on uremic toxins.
    Neirynck N; Vanholder R; Schepers E; Eloot S; Pletinck A; Glorieux G
    Int Urol Nephrol; 2013 Feb; 45(1):139-50. PubMed ID: 22893494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Online hemodiafiltration.
    Van Laecke S; De Wilde K; Vanholder R
    Artif Organs; 2006 Aug; 30(8):579-85. PubMed ID: 16911311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Markers and possible uremic toxins: Japanese experiences.
    Kinugasa E
    Contrib Nephrol; 2011; 168():134-138. PubMed ID: 20938133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Uremic Toxins: how can we improve the removal today?].
    Teatini U; Romei Longhena G
    G Ital Nefrol; 2017 Sep; 34(5):89-101. PubMed ID: 28963830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Depurative efficiency of intermediate and large molecules with different hemodialysis modalities].
    Maduell F
    Nefrologia; 2005; 25 Suppl 2():15-8. PubMed ID: 16050396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular burden associated with uremic toxins in patients with chronic kidney disease.
    Moradi H; Sica DA; Kalantar-Zadeh K
    Am J Nephrol; 2013; 38(2):136-48. PubMed ID: 23941724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Membrane requirements for high-flux and convective therapies.
    Bowry SK
    Contrib Nephrol; 2011; 175():57-68. PubMed ID: 22188688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein-bound toxins--update 2009.
    Jourde-Chiche N; Dou L; Cerini C; Dignat-George F; Vanholder R; Brunet P
    Semin Dial; 2009; 22(4):334-9. PubMed ID: 19708977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advantages of new hemodialysis membranes and equipment.
    Vanholder R; Glorieux G; Van Biesen W
    Nephron Clin Pract; 2010; 114(3):c165-72. PubMed ID: 19955821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of removal capacity of two consecutive generations of high-flux dialysers during different treatment modalities.
    Meert N; Eloot S; Schepers E; Lemke HD; Dhondt A; Glorieux G; Van Landschoot M; Waterloos MA; Vanholder R
    Nephrol Dial Transplant; 2011 Aug; 26(8):2624-30. PubMed ID: 21310741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [On-line HFR and removal of uremic toxins inducing the loss of phospholipidic asymmetry of the erythrocyte membrane].
    Sirolli V; Cappelli P; Amoroso L; Di Liberato L; Muscianese P; Santarelli P; Del Rosso G; Bonomini M
    G Ital Nefrol; 2004; 21 Suppl 30():S208-11. PubMed ID: 15750987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical cross-over comparison of mid-dilution hemodiafiltration using a novel dialyzer concept and post-dilution hemodiafiltration.
    Krieter DH; Falkenhain S; Chalabi L; Collins G; Lemke HD; Canaud B
    Kidney Int; 2005 Jan; 67(1):349-56. PubMed ID: 15610261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Removal of uraemic retention solutes in standard bicarbonate haemodialysis and long-hour slow-flow bicarbonate haemodialysis.
    Basile C; Libutti P; Di Turo AL; Casino FG; Vernaglione L; Tundo S; Maselli P; De Nicolò EV; Ceci E; Teutonico A; Lomonte C
    Nephrol Dial Transplant; 2011 Apr; 26(4):1296-303. PubMed ID: 20813765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uremic toxins: a new focus on an old subject.
    Yavuz A; Tetta C; Ersoy FF; D'intini V; Ratanarat R; De Cal M; Bonello M; Bordoni V; Salvatori G; Andrikos E; Yakupoglu G; Levin NW; Ronco C
    Semin Dial; 2005; 18(3):203-11. PubMed ID: 15934967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of protein-bound toxins, possibility for blood purification therapy.
    Neirynck N; Glorieux G; Schepers E; Pletinck A; Dhondt A; Vanholder R
    Blood Purif; 2013; 35 Suppl 1():45-50. PubMed ID: 23466378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.